Literature DB >> 10958212

Smoking and inflammatory bowel disease.

D T Rubin1, S B Hanauer.   

Abstract

It is well established that smoking cigarettes is associated with Crohn's disease (CD) and that non-smoking is associated with ulcerative colitis (UC). Furthermore, there is convincing evidence that smoking cigarettes has a negative effect on the course of CD, and that smoking cigarettes may improve the disease severity or have a 'protective' effect in some patients with UC. Despite these well-described associations, the mechanism by which cigarette smoking affects CD and UC is not known. Researchers have studied the systemic effects, cellular and humoral immune effects, mucosal changes, and the intestinal permeability changes with inflammatory bowel disease (IBD) and smoking. To date, none of these studies adequately explains the observed clinical patterns. It has been assumed that nicotine is the active agent in these associations, but clinical trials of nicotine chewing gum and transdermal nicotine in UC have shown limited benefit, and have been complicated by significant side-effects. Topical delivery systems for nicotine therapy are currently under development and await future clinical trials.

Entities:  

Mesh:

Year:  2000        PMID: 10958212     DOI: 10.1097/00042737-200012080-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  34 in total

Review 1.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Appendix redux.

Authors:  D B Sachar
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

3.  Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery.

Authors:  Myles R Joyce; Christine D Hannaway; Scott A Strong; Victor W Fazio; Ravi P Kiran
Journal:  Langenbecks Arch Surg       Date:  2011-10-22       Impact factor: 3.445

4.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 5.  Nicotinic modulation of innate immune pathways via α7 nicotinic acetylcholine receptor.

Authors:  Wen-Yan Cui; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-13       Impact factor: 4.147

Review 6.  From smoking to lung cancer: the CHRNA5/A3/B4 connection.

Authors:  M R D Improgo; M D Scofield; A R Tapper; P D Gardner
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

Review 7.  Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future?

Authors:  Arthur Kaser; Sebastian Zeissig; Richard S Blumberg
Journal:  Dig Dis       Date:  2010-09-30       Impact factor: 2.404

8.  DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.

Authors:  Edel McDermott; Elizabeth J Ryan; Miriam Tosetto; David Gibson; Joe Burrage; Denise Keegan; Kathryn Byrne; Eimear Crowe; Gillian Sexton; Kevin Malone; R Alan Harris; Richard Kellermayer; Jonathan Mill; Garret Cullen; Glen A Doherty; Hugh Mulcahy; Therese M Murphy
Journal:  J Crohns Colitis       Date:  2015-09-28       Impact factor: 9.071

Review 9.  The epidemiology and risk factors of inflammatory bowel disease.

Authors:  Yulan Ye; Zhi Pang; Weichang Chen; Songwen Ju; Chunli Zhou
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 10.  Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics.

Authors:  S J Gibbons; P-J Verhulst; A Bharucha; G Farrugia
Journal:  Aliment Pharmacol Ther       Date:  2013-08-28       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.